340B Contract Pharmacy Map
The 340B network as a graph.
Manufacturer restrictions mapped.
HRSA publishes 340B covered entity and contract pharmacy data — but nobody has built the network. Which DSH hospitals route through which pharmacies, what the revenue exposure is, and who's affected by manufacturer restrictions. Built from HRSA OPAIS. Rebuilt monthly.
Institutional license. Entity-side, manufacturer-side, or both.
What the map contains
Every 340B covered entity mapped to every contract pharmacy it registers with HRSA. Every contract pharmacy reverse-indexed to the covered entities it serves. Manufacturer restriction status overlaid by entity, product, and pharmacy.
| Covered Entity | Entity Type | Contract Pharmacies | Active Restrictions | Restricted Manufacturers |
|---|---|---|---|---|
| Advocate Aurora Health | DSH Hospital | 47 | Yes | Lilly, Sanofi, Novo Nordisk, AZ |
| Community Health Network (IN) | DSH Hospital | 22 | Yes | Lilly, Sanofi |
| HealthRight 360 | Federally Qualified Health Center | 6 | No | — |
| Denver Health Medical Center | DSH Hospital | 11 | Yes | Lilly, AstraZeneca, Boehringer |
| Cherokee Health Systems | FQHC | 3 | No | — |
Sample from HRSA OPAIS public extract. Manufacturer restrictions as of most recent update. Full graph includes 14,000+ covered entities and 40,000+ contract pharmacy relationships.
Active manufacturer restrictions tracked
| Manufacturer | Restriction type | Products affected | Effective | Status |
|---|---|---|---|---|
| Eli Lilly | One contract pharmacy per entity (DSH) | Insulin products, Taltz, Verzenio, others | Jan 2021 | Active — in litigation |
| Sanofi | One contract pharmacy per entity | Dupixent, Kevzara, Praluent | Sep 2020 | Active |
| Novo Nordisk | One contract pharmacy per entity | Ozempic, Victoza, NovoLog, others | Dec 2020 | Active |
| AstraZeneca | Claims data required for non-Medicaid populations | Farxiga, Brilinta, Lynparza, others | Jul 2021 | Active |
| Boehringer Ingelheim | One contract pharmacy per entity | Jardiance, Ofev, Spiriva, others | Sep 2021 | Active |
Restriction terms and product lists verified from manufacturer policy notices and Federal Register postings. Updated as manufacturers modify terms.
Who buys it
Healthcare PE — Entity Side
Underwriting a 340B-dependent platform deal (community oncology, FQHC roll-up, dialysis adjacency)? The map sizes the revenue at stake from any given manufacturer restriction and identifies covered-entity concentration risk before LOI.
Pharma — Manufacturer Side
The same network answers the inverse question: which entities and pharmacies represent the largest exposure to a proposed restriction, and where litigation risk concentrates. Modeled before the policy goes live, not after the lawsuit is filed.
340B Program Directors
Covered entities tracking peer-network behavior, monitoring restriction status across their own contract pharmacy relationships, and preparing for HRSA audits. Exportable entity-specific report included.
Primary data sources
| Source | What it provides | Update cadence |
|---|---|---|
| HRSA OPAIS | Covered entity database, contract pharmacy database, registered relationships | Monthly public extract |
| Manufacturer 340B restriction notices | Active restrictions by manufacturer and product, effective dates | Continuous (event-driven) |
| CMS Medicare cost reports | DSH percentage, hospital size and case mix for entity-class validation | Annual |
| Federal Register and HRSA dispute postings | Active disputes, HRSA ADR outcomes, policy developments | Continuous |
Inquire about access
340B Contract Pharmacy Map is sold under named institutional license. Pricing scales with whether you need the entity-side cut, the manufacturer-side cut, or both. Reach out with your organization and use case.